M28 Capital Management LP
In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 14, 2026), M28 Capital Management LP reported 9 stock positions worth $53.8 million. Its top holding was Wave Life Sciences (WVE) at 61.8% of the portfolio, followed by Invivyd (IVVD, 22.3%) and TG Therapeutics (TGTX, 5.5%). Compared with Q4 2025, it reduced 7. The biggest sale was Wave Life Sciences (WVE, shares −19%).
- Most Recent 13F
- Q2 2026
- Location
- STAMFORD, CT
- CIK
- 0001807489
- Portfolio Value
- $53.8M (Q1 2026)
- SEC Filing
- 0000902664-26-002442 ↗ filed May 14, 2026
Holdings Value
Holdings 9 stocks · $53.8M
| WVE Wave Life Sciences Ltd. | 61.83% | 4,588,284 | $33.3M | Reduce -19.0% |
| IVVD Invivyd Inc. | 22.35% | 9,248,250 | $12.0M | No change |
| TGTX TG Therapeutics Inc. | 5.46% | 88,354 | $2.9M | Reduce -45.3% |
| ARWR Arrowhead Pharmaceuticals Inc. | 4.29% | 36,851 | $2.3M | Reduce -45.3% |
| PRQR Proqr Therapeutics NV | 1.81% | 599,793 | $972K | Reduce -41.2% |
| GUTS Fractyl Health Inc. | 1.58% | 1,856,117 | $850K | No change |
| RCKT Rocket Pharmaceuticals Inc. | 1.40% | 210,871 | $755K | Reduce -45.3% |
| SLN Silence Therapeutics PLC-ADR | 0.99% | 101,203 | $533K | Reduce -45.3% |
| CRIS Curis Inc. | 0.29% | 284,889 | $156K | Reduce -45.3% |
Portfolio Sells Q4 2025 → Q1 2026
| WVE Wave Life Sciences Ltd. | Reduce -19.0% | 61.83% | −8.17 |
| CRIS Curis Inc. | Reduce -45.3% | 0.29% | −0.08 |
| SLN Silence Therapeutics PLC-ADR | Reduce -45.3% | 0.99% | +0.17 |
| PRQR Proqr Therapeutics NV | Reduce -41.2% | 1.81% | +0.31 |
| RCKT Rocket Pharmaceuticals Inc. | Reduce -45.3% | 1.40% | +0.42 |
| ARWR Arrowhead Pharmaceuticals Inc. | Reduce -45.3% | 4.29% | +1.04 |
| TGTX TG Therapeutics Inc. | Reduce -45.3% | 5.46% | +1.95 |
Portfolio Buys Q4 2025 → Q1 2026
| None this quarter. | |||
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 9 | $47.2M | WVE, IVVD, TGTX, ARWR, GUTS |
| Q1 2026 | 9 | $53.8M | WVE, IVVD, TGTX, ARWR, PRQR |
| Q4 2025 | 9 | $137.6M | WVE, IVVD, TGTX, ARWR, GUTS |
| Q3 2025 | 9 | $68.0M | WVE, IVVD, TGTX, GUTS, ARWR |
| Q2 2025 | 9 | $58.6M | WVE, IVVD, TGTX, GUTS, PRQR |
| Q1 2025 | 11 | $73.0M | WVE, TGTX, IVVD, BBIO, RCKT |
| Q4 2024 | 11 | $101.9M | WVE, TGTX, RCKT, IVVD, SWTX |
| Q3 2024 | 11 | $91.0M | WVE, IVVD, RCKT, GUTS, TGTX |
| Q2 2024 | 11 | $77.1M | WVE, IVVD, RCKT, GUTS, SWTX |
| Q1 2024 | 11 | $135.3M | WVE, IVVD, GUTS, RCKT, SLN |